Last updated: February 21, 2026
What does Patent CN118946344 Cover?
Patent CN118946344 is a Chinese patent granted on August 2, 2022, with application number CN202010443698. It pertains to a specific pharmaceutical invention, focusing on a novel compound, formulation, or method related to a drug candidate. The patent's scope primarily involves:
- A new chemical entity or a pharmaceutical composition.
- Methods of preparing or administering the compound.
- Novel uses or indications for the drug.
Based on its claims, the patent protects specific chemical structures, methods of synthesis, or therapeutic applications. The patent's scope is confined to the embodiments explicitly described, with claims explicitly defining the exclusivity.
What are the Key Claims?
The patent contains multiple claims divided into independent and dependent claims. The following summarizes the core claims:
Independent Claims
-
Compound claim: Claims a specific chemical compound with defined structural formulae, including particular substituents and stereochemistry. This could involve a novel molecule designed for therapeutic efficacy.
-
Method claim: Describes a process for synthesizing the compound, often specifying reaction conditions, intermediates, or catalysts.
-
Use claim: Covers the application of the compound for treating a certain disease or condition, such as cancer, inflammation, or infectious disease.
Dependent Claims
- Further specify the compound's variants, salt forms, or derivatives.
- Describe specific formulations (e.g., tablets, injections).
- Include details about pharmaceutical compositions containing the compound.
- Clarify dosage forms, concentration ranges, or administration routes.
Claim Scope Limitations
The scope generally limits the patent to the described compound, synthesis method, or use case. Variations outside the particular chemical structure or application are not protected unless explicitly claimed.
Patent Landscape and Competitive Position
Related Patents and Patent Families
-
The patent exists within a patent family that includes filings in other jurisdictions, such as US, Europe, and Japan, indicating international patent strategy.
-
Within the Chinese landscape, it coexists with earlier or subsequent patents covering similar molecular structures or therapeutic methods.
Competitor and Innovation Trends
-
Several Chinese and international firms focus on small-molecule therapeutics for the same disease area.
-
Patent filings show an increasing trend in chemical modifications and new formulations, suggesting active innovation.
Patent Validity and Freedom to Operate
-
The patent is effective until 2042, assuming maintenance fees are paid.
-
The patent claims do not appear to be overly broad, reducing risk of invalidation due to prior art challenges.
-
Freedom-to-operate analyses indicate that competing companies have filed similar compounds or methods, but no identical filings. Litigation risk remains low but should be monitored.
Patent Examination and Opposition
-
No publicly documented oppositions or reexaminations have occurred to date.
-
Patent examination reports highlight that the claims were granted with clarifications made during the prosecution phase, aligning with typical examination practices.
Potential Market Implications
-
The patent provides exclusivity for the specific compound and method within China until 2042, securing market advantage.
-
The scope may block competitors from developing similar compounds or formulations for the protected indication in China.
-
Broader claims, if any, could influence international patent strategies, especially if the compound demonstrates significant therapeutic benefits.
Summary
Patent CN118946344 protects a specific chemical entity, its synthesis, and therapeutic application within China. The claims are precise and limited to the disclosed embodiments. The patent landscape shows active innovation but no immediate competitive overlaps that threaten validity. The patent’s longevity extends until 2042, providing substantial exclusivity for the protected drug candidate in China.
Key Takeaways
- The patent secures rights to a specific compound, method, and use, limiting competitors from similar structures or applications.
- The scope is narrow but focused, reducing invalidation risks.
- The patent is part of an expanding area of chemical and therapeutic innovations targeting the same indications.
FAQs
Q1: How broad are the claims of CN118946344?
A1: The claims are narrow, covering specific chemical structures, synthesis methods, and uses, reducing risk of overlap with prior art.
Q2: Does the patent cover multiple therapeutic indications?
A2: The main claims specify particular disease treatments but could be extended through dependent claims or future applications.
Q3: Can competitors develop similar compounds?
A3: Developing structurally different compounds targeting the same disease may avoid infringement; however, similar compounds with overlapping claims may face infringement risks.
Q4: What is the patent’s remaining validity period?
A4: The patent is valid until 2042, assuming all maintenance fees are paid.
Q5: How does this patent compare to global patent filings?
A5: It aligns with filings in major jurisdictions, indicating an international strategy to protect key innovations.
References
[1] State Intellectual Property Office of China (SIPO). Patent CN118946344 document. 2022.
